Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2025-08-31 Governance Information
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
投资者关系管理制度
Governance Information Classification · 95% confidence The document is titled as an "Investor Relations Management System" issued by the company's board. It details the company's policies and procedures for managing investor relations, including communication principles, organizational responsibilities, disclosure requirements, and interaction with investors. It is a governance-related internal policy document rather than a financial report, earnings release, or announcement of voting results. It does not contain financial statements or results, nor is it a notice or announcement of a report publication. The content aligns with governance and internal management practices related to investor relations. Therefore, the most appropriate classification is Governance Information (CGR). The document length (5141 characters) and detailed policy content support this classification with high confidence.
2025-08-31 Chinese
关于控股子公司汇恩兰德完成股份制改造暨完成工商变更登记的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of a subsidiary's shareholding restructuring and the completion of related industrial and commercial registration changes. It details the change of the subsidiary to a joint-stock company and the registration of the new business license. The document is short (1032 characters) and serves as a formal announcement of a corporate structural change rather than a detailed financial report or management discussion. It does not contain financial statements or detailed financial data. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as shareholding restructuring.
2025-08-27 Chinese
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告" which translates to "Half-Year Report" or "Interim Report" for the period January 1, 2025 to June 30, 2025. It contains detailed financial data including income statement, balance sheet, cash flow, and extensive management discussion on business operations, industry overview, and financial analysis. The document length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. It explicitly states it is a half-year report and includes actual financial statements and substantive financial data. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-27 Chinese
第六届董事会第二十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 21st meeting of the 6th Board of Directors of Beijing Northland Biotechnology Co., Ltd. It details the meeting's attendance, the approval of the 2025 semi-annual report and related summary, and the approval of a special report on the management and use of raised funds. The document references the actual semi-annual report and special report as being published separately on the Beijing Stock Exchange information disclosure platform, indicating this document is not the report itself but an announcement of board resolutions related to these reports. The document length is short (1556 characters) and it does not contain substantive financial data or the full report content. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a formal regulatory announcement of board meeting resolutions and references other filings rather than containing the full financial report or detailed financial data itself.
2025-08-27 Chinese
第六届监事会第十五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board (监事会) of Beijing Northland Biotechnology Co., Ltd. It details the meeting date, attendance, and the approval of two agenda items: the 2025 semi-annual report and a special report on the management and use of raised funds. The document states that the semi-annual report and related documents have been disclosed on the Beijing Stock Exchange website with specific announcement numbers. The document itself does not contain the financial statements or substantive financial data but rather the supervisory board's approval and opinions on these reports. The document length is short (1490 characters) and serves as a meeting resolution announcement rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice, not as the actual Interim/Quarterly Report (IR) or Annual Report (10-K).
2025-08-27 Chinese
2025年半年度募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2025 Semi-Annual Special Report on the Deposit, Management, and Actual Use of Raised Funds" by Beijing Northland Biotechnology Co., Ltd. It details the company's fundraising activities, including stock issuance approvals by the China Securities Regulatory Commission, amounts raised, usage of funds, and management of idle raised funds. The document includes detailed tables on the use of raised funds, project progress, and compliance with regulations. It is a comprehensive report focused specifically on the management and use of capital raised through stock issuance, not a general financial report or earnings release. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length (8260 characters) and detailed content confirm it is the report itself, not just an announcement or certification. Therefore, the correct classification is CAP with high confidence.
2025-08-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.